Public Comments to Singapore’s Bioethics Advisory Committee on Mitochondrial Replacement Therapy

Posted on Jul 26, 2018

In the Spring of 2018, Singapore issued a call for Public Comments on the topic of whether it should repeal the country’s current prohibition against germline modification of embryos and permit an exception for Mitochondrial Replacement Therapy.


See the story here and here.


In response, I submitted Public Comments against modifying Singapore’s law, arguing science, policy, and ethics supports a continued prohibition against Mitochondrial Replacement Therapy.


A copy of my Comments to the Singapore Bioethics Advisory Committee are here:

 Drabiak Mitochondrial Genome Replacement Technology Public Comments.